REDDIT · REDDIT// 26d agoVIDEO

Max Hodak maps BCI path to scale

In this Y Combinator podcast episode, Neuralink co-founder Max Hodak outlines how Science Corporation is using its PRIMA retinal implant to restore functional vision in patients with advanced macular degeneration, while arguing that vision restoration is just the first commercial wedge for broader brain-computer interfaces. The discussion blends current clinical progress with longer-term bets on higher-bandwidth neural interfaces and AI-neuroscience convergence.

// ANALYSIS

The big signal here is that BCIs are shifting from speculative moonshots to productizable medical systems, but the path to mass adoption still runs through hard clinical, safety, and cost constraints.

–Science positions PRIMA as a practical near-term BCI: a specific disease target, defined trial endpoints, and a regulatory pathway.
–Reported reading gains in trial participants make this more than a lab demo, but outcomes still depend on training, device limits, and patient selection.
–Hodak’s framing suggests the market will expand from therapeutic use cases (vision loss, paralysis) before any enhancement-focused consumer narrative.
–The interview also surfaces the strategic tension: AI-era ambition is huge, but trust will be won or lost on safety, durability, and reimbursement.

// TAGS

science-corporationneuralinkbrain-computer-interfacevision-restorationbiotechresearchpodcast

DISCOVERED

26d ago

2026-03-17

PUBLISHED

26d ago

2026-03-16

RELEVANCE

6/ 10

AUTHOR

44th--Hokage